Two Biosimilar Guidances on FDA’s 2013 Agenda But No Interchangeability

Generic Line
The FDA plans to release two guidances to assist biosimilar sponsors this year, but drugmakers hoping for advice on how to achieve the coveted interchangeable designation shouldn’t get their hopes up.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00